Commit welcomes Anker Lundemose as executive chairman of the board. MD, PhD Anker Lundemose is CEO at Mission Therapeutics (backed by Sofinnova Partners, Roche Venture Fund, Pfizer Ventures and SR One) and has held numerous management and board positions in high-profile biotech companies. With extensive experience in business development, corporate development, M&A strategy and execution, financing as well as R&D, Anker will help set the direction and shape the future of Commit biologics.
Read more at Medwatch
